• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Kamada Ltd.

    11/14/24 6:21:51 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KMDA alert in real time by email
    SC 13G/A 1 zk2432314.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 17)*
     
    Kamada Ltd.
    (Name of Issuer)

    Ordinary Shares, par value NIS 1.00 each
     (Title of Class of Securities)

    M6240T109 
     (CUSIP Number)
     
    September 30, 2024
     (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. M6240T109
    13G
    Page 2 of 8 Pages

    1
    NAME OF REPORTING PERSONS
     
    Phoenix Financial Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a)  ☐
    (b)  ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER
     
    4,138,808.98 (*)
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
    4,138,808.98 (*)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    4,138,808.98 (*)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    7.2% (*)(**)
    12
    TYPE OF REPORTING PERSON   (See instructions)
     
    CO
     
    (*) The beneficial ownership of the securities reported herein is described in Item 4(a).

    (**) Based on 57,485,615 Ordinary Shares outstanding as of October 15, 2024 (as reported on Bloomberg LP).

    2

     

    Item 1. (a)               Name of Issuer:
     
    Kamada Ltd.

                 (b)
    Address of Issuer's Principal Executive Offices:

     2 Holtzman St., Science Park, P.O. Box 4081, Rehovot 7670402, Israel
     
    Item 2. (a)
    Name of Person Filing:

     
    Phoenix Financial Ltd.

    The securities reported herein are beneficially owned by various direct or indirect, majority or wholly-owned subsidiaries of Phoenix Financial Ltd. (the "Subsidiaries").  The Subsidiaries manage their own funds and/or the funds of others, including for holders of exchange-traded notes or various insurance policies, members of pension or provident funds, unit holders of mutual funds, and portfolio management clients.  Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.

     
    (b)
    Address of Principal Business Office:

    The address of Phoenix Financial Ltd. is Derech Hashalom 53, Givataim, 53454, Israel.

     
    (c)
    Citizenship:

     
    Phoenix Financial Ltd. - Israel

     
    (d)
    Title of Class of Securities:
     
    Ordinary Shares, par value NIS 1.00 each

     
    (e)
    CUSIP Number:

    M6240T109
     
    3

     
    Item 3.
    Not applicable.

    Item 4.
    Ownership:

     
    (a)
    Amount beneficially owned:

     
    See row 9 of cover page of each reporting person.
     
     
    Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.  Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by either the Filing Persons or Subsidiaries that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each reporting person disclaims the existence of any such group.  In addition, each of the Filing Persons and Subsidiaries disclaims any beneficial ownership of the securities covered by this report in excess of their actual pecuniary interest therein. This Statement shall not be construed as an admission by the Filing Persons or Subsidiaries that they are the beneficial owners of any of the Ordinary Shares covered by this Statement.

     As of September 30, 2024, the securities reported herein were held as follows:

       
    Ordinary
    Shares
       
    Percentage of total Ordinary Shares outstanding
     
    The Phoenix Investments House -  "nostro" accounts
       
    --
         
    --
     
    The Phoenix Investments House - trust funds
       
    153,495.86
         
    0.27
    %
    The Phoenix Investments House -  ETF's
       
    --
         
    --
     
    The Phoenix "nostro" accounts
       
    --
         
    --
     
    The Phoenix pension and provident funds
       
    --
         
    --
     
    Linked insurance policies of Phoenix
       
    --
         
    --
     
    Partnership for Israeli shares (1)
       
    3,791,052
         
    6.59
    %
    Partnership for investing in shares indexes (1)
       
    194,261.12
         
    0.34
    %
    Halman - Aldubi Provident and Pension Funds Ltd.
       
    --
         
    --
     

    (1) All ownership rights in this partnership belong to companies that are part of Phoenix Group. The amount of ownership rights held by such companies in the partnership changes frequently according to a mechanism provided in the partnership agreement

     
    (b)
    Percent of class:

     
    See row 11 of cover page of each reporting person

     
    4

     

     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote:
     
    See row 5 of cover page of each reporting person
     
     
    (ii)
    Shared power to vote or to direct the vote:
     
    See row 6 of cover page of each reporting person and note in Item 4(a) above
     
     
    (iii)
    Sole power to dispose or to direct the disposition of:
     
    See row 7 of cover page of each reporting person
     
     
    (iv)
    Shared power to dispose or to direct the disposition of:
     
    See row 8 of cover page of each reporting person and note in Item 4(a) above
     
    Item 5.
    Ownership of Five Percent or Less of a Class:

    Not applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another:

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group:

    Not applicable.

    Item 9.
    Notice of Dissolution of Group:

    Not applicable.
     
     
    5

     
     
    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
     6

     
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    November 13, 2024
     
       
    Phoenix Financial Ltd.
     
    /s/ Eli Schwartz
    By: Eli Schwartz*
    Title: Executive Vice President - Chief Financial Officer

       
    /s/ Haggai Schreiber
    By: Haggai Schreiber*
    Title: Executive Vice President - Chief Investment Officer

    * Signature duly authorized by resolution of the Board of Directors, notice of which is attached as Exhibit 1 to this Schedule 13G.

    7

     
     
    EXHIBIT NO.
    DESCRIPTION
     
         
    Exhibit 1
    Notice of resolution of the Board of Directors of Phoenix Financial Ltd., dated as of December 12, 2019 (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on February 7, 2022).
     

    8


    Get the next $KMDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KMDA

    DatePrice TargetRatingAnalyst
    3/21/2025$15.00Buy
    The Benchmark Company
    7/3/2024$18.00Buy
    Stifel
    More analyst ratings

    $KMDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

      Funding Strengthens Kamada's Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced shareholder approval and planned closing of the previously announced $60 million private placement (the "Private Placement") with FIMI Op

      8/30/23 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

      REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))) ("Kamada" or the "Company"), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth of its existing business and allow the Company to pursue compelling business development opportunities, Chief Financial Officer (CFO), Chaime Orlev, who had previously planned to transition out of h

      5/24/23 7:05:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

      Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year IncreaseFirst Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-YearStrong Financial Position to Accelerate Growth Through M&A and/or In-licensing Opportunities Announced Expansion of Plasma Collection Operations with Opening of New Site in San Antonio, TexasLaunched Comprehensive Post-Marketing Research Program of CYTOGAM®Reiterating Full Year 2025 Guidance, Representing Double Digit Profitable Growth Year-over-Year Conference Call and Live Webcast Today at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharm

      5/14/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

      REHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter that ended March 31, 2025, prior to the open of the U.S. financial markets on Wednesday, May 14, 2025. Kamada management will host an investment community conference call on Wednesday, May 14, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in

      5/7/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

      Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ TransplantationA Total of 10 Studies will be Conducted in Collaboration with Leading U.S. Physicians, Primarily as Investigator-Initiated Studies (IIS)Results of the Planned Studies are Expected to be Published and/or Presented in Peer Reviewed Industry Journals and Medical Meetings in the Coming Years REHOVOT, Israel, and HOBOKEN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty

      5/5/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Benchmark Company initiated coverage on Kamada with a new price target

      The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00

      3/21/25 8:11:15 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Kamada with a new price target

      Stifel initiated coverage of Kamada with a rating of Buy and set a new price target of $18.00

      7/3/24 7:31:15 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kamada Ltd.

      SC 13G/A - KAMADA LTD (0001567529) (Subject)

      11/14/24 6:21:51 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

      SC 13G/A - KAMADA LTD (0001567529) (Subject)

      2/14/24 5:04:02 PM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

      SC 13G/A - KAMADA LTD (0001567529) (Subject)

      2/12/24 12:41:57 PM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMDA
    Financials

    Live finance-specific insights

    See more
    • Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

      Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year IncreaseFirst Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-YearStrong Financial Position to Accelerate Growth Through M&A and/or In-licensing Opportunities Announced Expansion of Plasma Collection Operations with Opening of New Site in San Antonio, TexasLaunched Comprehensive Post-Marketing Research Program of CYTOGAM®Reiterating Full Year 2025 Guidance, Representing Double Digit Profitable Growth Year-over-Year Conference Call and Live Webcast Today at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharm

      5/14/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

      REHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter that ended March 31, 2025, prior to the open of the U.S. financial markets on Wednesday, May 14, 2025. Kamada management will host an investment community conference call on Wednesday, May 14, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in

      5/7/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders

      REHOVOT, Israel and HOBOKEN, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the "Ruling") from the Israel Tax Authority (the "ITA") with respect to the special cash dividend of $0.20 (approximately NIS 0.72) per share on the Company's ordinary shares (totaling approximately $11.5 million) announced on March 5, 2025 (the "Dividend"), expected to be paid on April 7, 2025 (the "Payment Date"), to shareholders of record at the close of busines

      3/24/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMDA
    SEC Filings

    See more
    • SEC Form 6-K filed by Kamada Ltd.

      6-K - KAMADA LTD (0001567529) (Filer)

      5/14/25 7:00:26 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Kamada Ltd.

      6-K - KAMADA LTD (0001567529) (Filer)

      5/7/25 7:07:41 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Kamada Ltd.

      6-K - KAMADA LTD (0001567529) (Filer)

      5/5/25 7:00:24 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care